Home >> Research Area >>DNA Damage/DNA Repair>>HDAC>> CI994 (Tacedinaline)

CI994 (Tacedinaline)

HDAC inhibitor CAS# 112522-64-2

CI994 (Tacedinaline)

Catalog No. BCC2159----Order now to get a substantial discount!

Product Name & Size Price Stock
CI994 (Tacedinaline): 5mg $23 In Stock
CI994 (Tacedinaline): 10mg Please Inquire In Stock
CI994 (Tacedinaline): 20mg Please Inquire Please Inquire
CI994 (Tacedinaline): 50mg Please Inquire Please Inquire
CI994 (Tacedinaline): 100mg Please Inquire Please Inquire
CI994 (Tacedinaline): 200mg Please Inquire Please Inquire
CI994 (Tacedinaline): 500mg Please Inquire Please Inquire
CI994 (Tacedinaline): 1000mg Please Inquire Please Inquire
Related Products

Quality Control of CI994 (Tacedinaline)

Number of papers citing our products

Chemical structure

CI994 (Tacedinaline)

3D structure

Chemical Properties of CI994 (Tacedinaline)

Cas No. 112522-64-2 SDF Download SDF
PubChem ID 2746 Appearance Powder
Formula C15H15N3O2 M.Wt 269.3
Type of Compound N/A Storage Desiccate at -20°C
Synonyms Acetyldinaline; Tacedinaline; PD 123654; Goe 5549
Solubility DMSO : ≥ 58 mg/mL (215.37 mM)
*"≥" means soluble, but saturation unknown.
Chemical Name 4-acetamido-N-(2-aminophenyl)benzamide
SMILES CC(=O)NC1=CC=C(C=C1)C(=O)NC2=CC=CC=C2N
Standard InChIKey VAZAPHZUAVEOMC-UHFFFAOYSA-N
Standard InChI InChI=1S/C15H15N3O2/c1-10(19)17-12-8-6-11(7-9-12)15(20)18-14-5-3-2-4-13(14)16/h2-9H,16H2,1H3,(H,17,19)(H,18,20)
General tips For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.
We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months.
Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it.
About Packaging 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial.
2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial.
3. Try to avoid loss or contamination during the experiment.
Shipping Condition Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request.

Biological Activity of CI994 (Tacedinaline)

DescriptionCI-994 (Tacedinaline),an anti-cancer drug, is an inhibitor of HDAC1 with IC50 of 0.57 μM and causes G1 cell cycle arrest.
TargetsHDAC1    
IC500.57 μM     

Protocol

Cell experiment: [1]

Cell lines

Peripheral blood lymphocytes

Preparation method

The solubility of this compound in DMSO is >10 mM. General tips for obtaining a higher concentration: Please warm the tube at 37 °C for 10 minutes and/or shake it in the ultrasonic bath for a while.Stock solution can be stored below -20°C for several months.

Reacting condition

10 µM, 24 hours

Applications

No evidence of apoptosis or necrosis was detected in lymphocytes exposed to CI994 for 4 hours. After 24 hours, concentration-dependent increases in apoptosis characterized by DNA condensation, DNA fragmentation, and/or externalization of phosphatidyl serine were seen at CI-994 concentrations as low as 1 µM and were statistically significant beginning at 10 µM.

Animal experiment: [2]

Animal models

Male Wistar rats

Dosage form

Oral administration, 45 mg/kg

Application

15 rats per group were administered a single dose of CI994 at 0 (vehicle control), 10, 23, and 45 mg/kg. 5 rats per group were killed 1, 3, and 7 days after dosing for evaluation of blood and bone marrow lymphocyte counts. CI994 treatments resulted in significant dose-related reductions in total white blood cell counts, total lymphocytes and lymphocyte subpopulations. Relative to controls, reductions on day 1 ranged from 36 to 48% at 10 mg/kg, 65 to 76% at 23 mg/kg, and 74 to 87%at 45 mg/kg. Dose-related reductions in monocytes ranging from 54 to 89% were observed in all drug-treated groups on days 1 and 3. Besides that, significant dose-related reductions in bone marrow lymphoid cells ranged from 28 to 33% at 10 mg/kg, 63 to 69%at 23 mg/kg, and 80 to 87%at 45 mg/kg.

Other notes

Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal.

References:

[1] Graziano M J, Spoon T A, Cockrell E A, et al. Induction of apoptosis in rat peripheral blood lymphocytes by the anticancer drug CI-994 (acetyldinaline). BioMed Research International, 2001, 1(2): 52-61.

[2] Graziano M J, Galati A J, Walsh K M. Immunotoxicity of the anticancer drug CI-994 in rats: effects on lymphoid tissue. Archives of toxicology, 1999, 73(3): 168-174.

CI994 (Tacedinaline) Dilution Calculator

Concentration (start)
x
Volume (start)
=
Concentration (final)
x
Volume (final)
 
 
 
C1
V1
C2
V2

calculate

CI994 (Tacedinaline) Molarity Calculator

Mass
=
Concentration
x
Volume
x
MW*
 
 
 
g/mol

calculate

Preparing Stock Solutions of CI994 (Tacedinaline)

1 mg 5 mg 10 mg 20 mg 25 mg
1 mM 3.7133 mL 18.5667 mL 37.1333 mL 74.2666 mL 92.8333 mL
5 mM 0.7427 mL 3.7133 mL 7.4267 mL 14.8533 mL 18.5667 mL
10 mM 0.3713 mL 1.8567 mL 3.7133 mL 7.4267 mL 9.2833 mL
50 mM 0.0743 mL 0.3713 mL 0.7427 mL 1.4853 mL 1.8567 mL
100 mM 0.0371 mL 0.1857 mL 0.3713 mL 0.7427 mL 0.9283 mL
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations.

Organizitions Citing Our Products recently

 
 
 

Calcutta University

University of Minnesota

University of Maryland School of Medicine

University of Illinois at Chicago

The Ohio State University

University of Zurich

Harvard University

Colorado State University

Auburn University

Yale University

Worcester Polytechnic Institute

Washington State University

Stanford University

University of Leipzig

Universidade da Beira Interior

The Institute of Cancer Research

Heidelberg University

University of Amsterdam

University of Auckland
TsingHua University
TsingHua University
The University of Michigan
The University of Michigan
Miami University
Miami University
DRURY University
DRURY University
Jilin University
Jilin University
Fudan University
Fudan University
Wuhan University
Wuhan University
Sun Yat-sen University
Sun Yat-sen University
Universite de Paris
Universite de Paris
Deemed University
Deemed University
Auckland University
Auckland University
The University of Tokyo
The University of Tokyo
Korea University
Korea University

Background on CI994 (Tacedinaline)

CI994 is a selective inhibitor of HDAC1 with IC50 value of 0.57 μM [1].
HDAC1 is an enzyme that encoded by HDAC1 and plays a pivotal role in regulating eukaryotic gene expression. It is also been reported that HDAC1 interacts with retinoblastoma tumor-suppressor protein which is a key element in the control of cell proliferation and differentiation. Many studies have shown that HDAC1 inhibition works as a promising therapy used for cancer treatment in clinic [2] [3].
CI994 is a selective HDAC1 and HDAC3 and is different from the reported unselective inhibitor SAHA. When tested with HeLa cervical carcinoma cells, CI994 treatment showed a selectivity inhibitory ability for HDAC1 and 3 with the IC50 was 43.5±1.2 μM [4]. In peripheral blood lymphocytes isolated from untreated male Wistar rats, administration of CI994 for 24 hours induced cells apoptosis in a dose-dependent manner (1 μM~10μM ) [1]. When tested with mitogen-stimulated blood lymphocytes, CI-994 treatment inhibited cells proliferation with IC50 value of 3 mM [5]. In NSCLC cell lines (A549 and LX-1), CI994 administration induced cell apoptosis via inhibiting HDAC activity and arresting cell cycle at G0/G1 phase and showed a promising therapy strategy when combined with chemotherapy [2].
In male rats model, oral administration of CI994 markedly effected lymphoid tissue via reducing blood lymphocytes, monocytes, neutrophils and bone marrow lymphoid cells at the concentration of 10, 23, and 45 mg/kg on day 1 and/or 3 [5].
References:
[1].    Graziano, M.J., et al., Induction of Apoptosis in Rat Peripheral Blood Lymphocytes by the Anticancer Drug CI-994 (Acetyldinaline)(*). J Biomed Biotechnol, 2001. 1(2): p. 52-61.
[2].    Loprevite, M., et al., In vitro study of CI-994, a histone deacetylase inhibitor, in non-small cell lung cancer cell lines. Oncol Res, 2005. 15(1): p. 39-48.
[3].    Cacan, E., et al., Inhibition of HDAC1 and DNMT1 modulate RGS10 expression and decrease ovarian cancer chemoresistance. PLoS One, 2014. 9(1): p. e87455.
[4].    Beckers, T., et al., Distinct pharmacological properties of second generation HDAC inhibitors with the benzamide or hydroxamate head group. Int J Cancer, 2007. 121(5): p. 1138-48.
[5].    Graziano, M.J., A.J. Galati, and K.M. Walsh, Immunotoxicity of the anticancer drug CI-994 in rats: effects on lymphoid tissue. Arch Toxicol, 1999. 73(3): p. 168-74.

Featured Products
New Products
 

Description

Tacedinaline (N-acetyldinaline) is an inhibitor of the histone deacetylase (HDAC) with IC50s of 0.9, 0.9, 1.2 μM for recombinant HDAC 1, 2 and 3 respectively.

Keywords:

CI994 (Tacedinaline),112522-64-2,Acetyldinaline; Tacedinaline; PD 123654; Goe 5549,Natural Products,HDAC, buy CI994 (Tacedinaline) , CI994 (Tacedinaline) supplier , purchase CI994 (Tacedinaline) , CI994 (Tacedinaline) cost , CI994 (Tacedinaline) manufacturer , order CI994 (Tacedinaline) , high purity CI994 (Tacedinaline)

Online Inquiry for:

      Fill out the information below

      • Size:Qty: - +

      * Required Fields

                                      Result: